{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:13:13Z","timestamp":1767993193243,"version":"3.49.0"},"reference-count":52,"publisher":"Index Copernicus","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Otolaryngol Pol"],"published-print":{"date-parts":[[2024,12,2]]},"abstract":"<ns3:p>Hypereosinophilic diseases represent a heterogeneous group that poses a significant medical challenge. An increased number of eosinophils in the blood can be a dominant symptom of hematologic diseases, such as myeloid hematopoietic cancers or lymphomas. However, it is more commonly associated with other health conditions, such as allergies, infections, and systemic inflammatory diseases. Distinguishing between eosinophilic vasculitis with polyangiopathy (EGPA) and idiopathic hypereosinophilic syndrome (I-HES) can be difficult in clinical practice. In this report, we provide practical guidelines for clinicians that may aid in the diagnosis and treatment of these diseases. Additionally, we discuss the role of biologic IL-5 inhibitors in their therapy, as mepolizumab is approved for the treatment of EGPA and I-HES. We believe that the proposed guidelines will be helpful for clinicians, especially those who are not familiar with hypereosinophilic diseases.<\/ns3:p>","DOI":"10.5604\/01.3001.0054.8684","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:11:04Z","timestamp":1759327864000},"page":"48-60","source":"Crossref","is-referenced-by-count":1,"title":["Hyper eosinophilic diseases \u2013 diagnosis and therapeutic approach \u2013 practical position of the Polish working group"],"prefix":"10.5604","volume":"78","author":[{"given":"Piotr","family":"Kuna","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Jassem","sequence":"additional","affiliation":[{"name":"Department of Pulmonology and Allergology, University of Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Wiatr","sequence":"additional","affiliation":[{"name":"Institute of Tuberculosis and Lung Diseases, Research Institute in Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanis\u0142awa","family":"Bazan-Socha","sequence":"additional","affiliation":[{"name":"Prof Andrzej Szczeklik 2nd Chair of Internal Medicine \u2013 Jagiellonian University Medical College in Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Kupry\u015b-Lipi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3689","reference":[{"key":"625711r1","doi-asserted-by":"crossref","unstructured":"Klion A.D.: How I treat hypereosinophilic syndromes. Blood., 2015; 126(9):1069\u20131077.","DOI":"10.1182\/blood-2014-11-551614"},{"key":"625711r2","doi-asserted-by":"crossref","unstructured":"Klion A.D., Bochner B.S., Gleich G.J. et al.: Approaches to the treatment ofhypereosinophilic syndromes: a workshop summary report., J Allergy ClinImmunol., 2006; 117(6): 1292\u20131302.","DOI":"10.1016\/j.jaci.2006.02.042"},{"key":"625711r3","doi-asserted-by":"crossref","unstructured":"Wardlaw A.J., Wharin S., Aung H., Shaffu S., Siddiqui S.: The causes of a peripheral blood eosinophilia in a secondary care setting. Clin Exp Allergy., 2021;51(7): 902\u2013914.","DOI":"10.1111\/cea.13889"},{"key":"625711r4","doi-asserted-by":"crossref","unstructured":"Shomali W., Gotlib J.: World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am JHematol., 2022; 97(1): 129\u2013148.","DOI":"10.1002\/ajh.26352"},{"key":"625711r5","doi-asserted-by":"crossref","unstructured":"Groh M., Pagnoux C., Baldini C. et al.: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendationsfor evaluation and management. Eur J Intern Med., 2015; 26(7): 545\u2013553.","DOI":"10.1016\/j.ejim.2015.04.022"},{"key":"625711r6","unstructured":"Cottin V., Bel E., Bottero P. et al.: Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patientsby the Groupe d\u2019Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev., 2017; 16(1): 1\u20139."},{"key":"625711r7","doi-asserted-by":"crossref","unstructured":"Klion A.: Hypereosinophilic syndrome: approach to treatment in the era of precision medicine. Hematol Am Soc Hematol Educ Progr., 2018; 2018(1): 326\u2013331.","DOI":"10.1182\/asheducation-2018.1.326"},{"key":"625711r8","doi-asserted-by":"crossref","unstructured":"Curtis C., Ogbogu P.: Hypereosinophilic Syndrome. Clin Rev Allergy Immunol., 2016; 50(2): 240\u2013251.","DOI":"10.1007\/s12016-015-8506-7"},{"key":"625711r9","doi-asserted-by":"crossref","unstructured":"Schwaab J., L\u00fcbke J., Reiter A., Metzgeroth G.: Idiopathic hypereosinophilicsyndrome \u2014 diagnosis and treatment. Allergo J Int., 2022; 31(7): 251\u2013256.","DOI":"10.1007\/s40629-022-00221-w"},{"key":"625711r10","doi-asserted-by":"crossref","unstructured":"Valent P., Gleich G.J., Reiter A. et al.: Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol., 2012; 5(2): 157\u2013176.","DOI":"10.1586\/ehm.11.81"},{"key":"625711r11","unstructured":"Khoury J.D., Solary E., Abla O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia., 2022; 36(7): 1703."},{"key":"625711r12","unstructured":"Grayson P.C., Ponte C., Suppiah R. et al.: 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology ClassificationCriteria for Eosinophilic Granulomatosis with polyangiitis. Ann Rheum Dis.,2022; 81(3): 309\u2013314."},{"key":"625711r13","doi-asserted-by":"crossref","unstructured":"Furuta S., Iwamoto T., Nakajima H.: Update on eosinophilic granulomatosispolyangiitis. Allergol Int., 2019; 68(4): 430\u2013436.","DOI":"10.1016\/j.alit.2019.06.004"},{"key":"625711r14","doi-asserted-by":"crossref","unstructured":"Szczeklik W., Soko\u0142owska B., Mastalerz L. et al. Pulmonary findings in Churg--Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol. 2010; 29(10): 1127\u20131134.","DOI":"10.1007\/s10067-010-1530-3"},{"key":"625711r15","doi-asserted-by":"crossref","unstructured":"Cottin V., Bel E., Bottero P. et al.: Respiratory manifestations of eosinophilicgranulomatosis with polyangiitis (Churg-Strauss). Eur Respir J., 2016; 48(5):1429\u20131441.","DOI":"10.1183\/13993003.00097-2016"},{"key":"625711r16","doi-asserted-by":"crossref","unstructured":"Kawakami T., Soma Y., Kawasaki K., Kawase A., Mizoguchi M.: Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg--Strauss syndrome. Arch Dermatol., 2005; 141(7): 873\u2013878.","DOI":"10.1001\/archderm.141.7.873"},{"key":"625711r17","doi-asserted-by":"crossref","unstructured":"Sinico R.A., Toma L. Di, Maggiore U. et al. Renal involvement in Churg-Strausssyndrome. Am J Kidney Dis., 2006; 47(5): 770\u2013779.","DOI":"10.1053\/j.ajkd.2006.01.026"},{"key":"625711r18","doi-asserted-by":"crossref","unstructured":"Comarmond C., Pagnoux C., Khellaf M. et al.: Eosinophilic granulomatosiswith polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.Arthritis Rheum., 2013; 65(1): 270\u2013281.","DOI":"10.1002\/art.37721"},{"key":"625711r19","doi-asserted-by":"crossref","unstructured":"Marmursztejn J., Guillevin L., Trebossen R. et al.: Churg-Strauss syndromecardiac involvement evaluated by cardiac magnetic resonance imaging andpositron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford)., 2013; 52(4): 642\u2013650.","DOI":"10.1093\/rheumatology\/kes155"},{"key":"625711r20","doi-asserted-by":"crossref","unstructured":"Moller D., Tan J., Gauiran DT V. et al.: Causes of hypereosinophilia in 100 consecutive patients. Eur J Haematol., 2020; 105(3): 292\u2013301.","DOI":"10.1111\/ejh.13437"},{"key":"625711r21","doi-asserted-by":"crossref","unstructured":"Gibelin A., Maldini C., Mahr A.: Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. Semin RespirCrit Care Med., 2011; 32(3): 264\u2013273.","DOI":"10.1055\/s-0031-1279824"},{"key":"625711r22","doi-asserted-by":"crossref","unstructured":"W\u00f3jcik K., Wawrzycka-Adamczyk K., W\u0142udarczyk A. et al.: Clinical characteristics of Polish patients with ANCA-associated vasculitides-retrospectiveanalysis of POLVAS registry. Clin Rheumatol., 2019; 38(9): 2553\u20132563.","DOI":"10.1007\/s10067-019-04538-w"},{"key":"625711r23","doi-asserted-by":"crossref","unstructured":"Fijolek J., Wiatr E., Bujnowski P., Piotrowska-Kownacka D., Roszkowski-Sliz K.:Evaluation of prognostic factors for patients with eosinophilic granulomatosiswith polyangiitis recruited at the pneumonological centre and mainly ANCAnegativity: A retrospective analysis of a single cohort in Poland. Mod Rheumatol., 2023; 34(1): 157\u2013166.","DOI":"10.1093\/mr\/road001"},{"key":"625711r24","unstructured":"Jennette J.C., Falk R.J., Bacon P.A. et al.: 2012 revised International ChapelHill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum.,2013; 65(1): 1\u201311."},{"key":"625711r25","doi-asserted-by":"crossref","unstructured":"Trivioli G., Terrier B., Vaglio A.: Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. Rheumatology (Oxford).,2020; 59(Suppl 3): iii84\u201394.","DOI":"10.1093\/rheumatology\/kez570"},{"key":"625711r26","doi-asserted-by":"crossref","unstructured":"Trivioli G., Marquez A., Martorana D. et al.: Genetics of ANCA-associatedvasculitis: role in pathogenesis, classification and management. Nat Rev Rheumatol., 2022; 18(10): 559\u2013574.","DOI":"10.1038\/s41584-022-00819-y"},{"key":"625711r27","doi-asserted-by":"crossref","unstructured":"Jakiela B., Szczeklik W., Plutecka H. et al. Increased production of IL-5 anddominant Th2-type response in airways of Churg-Strauss syndrome patients.Rheumatol (United Kingdom)., 2012; 51(10): 1887\u20131893.","DOI":"10.1093\/rheumatology\/kes171"},{"key":"625711r28","doi-asserted-by":"crossref","unstructured":"Vega Villanueva K.L., Espinoza L.R.: Eosinophilic Vasculitis. Curr Rheumatol Rep., 2020; 22(1): 5.","DOI":"10.1007\/s11926-020-0881-2"},{"key":"625711r29","doi-asserted-by":"crossref","unstructured":"Choi Y.H., Im J.G., Han B.K. et al.: Thoracic manifestation of Churg-Strausssyndrome: radiologic and clinical findings. Chest., 2000; 117(1): 117\u2013124.","DOI":"10.1378\/chest.117.1.117"},{"key":"625711r30","doi-asserted-by":"crossref","unstructured":"Erzurum S.C., Underwood G.A., Hamilos D.L., Waldron J.A.: Pleural effusionin Churg-Strauss syndrome. Chest., 1989; 95(6): 1357\u20131359.","DOI":"10.1378\/chest.95.6.1357"},{"key":"625711r31","doi-asserted-by":"crossref","unstructured":"Takeuchi H., Kawamura K., Kawasaki T., Oka N.: Distinct features of hypereosinophilic syndrome with neuropathy from eosinophilic granulomatosis withpolyangiitis. Front Neurol., 2022; 13: 1057767.","DOI":"10.3389\/fneur.2022.1057767"},{"key":"625711r32","doi-asserted-by":"crossref","unstructured":"Wang S.A.: The Diagnostic Work-Up of Hypereosinophilia. Pathobiology.,2019; 86(1): 39\u201352.","DOI":"10.1159\/000489341"},{"key":"625711r33","doi-asserted-by":"crossref","unstructured":"Chang H.C., Chou P.C., Lai C.Y., Tsai H.H.: Antineutrophil Cytoplasmic Antibodies and Organ-Specific Manifestations in Eosinophilic Granulomatosiswith Polyangiitis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract., 2021; 9(1): 445\u2013452.e6.","DOI":"10.1016\/j.jaip.2020.07.038"},{"key":"625711r34","doi-asserted-by":"crossref","unstructured":"Wu E.Y., Hernandez M.L., Jennette J.C., Falk R.J.: Eosinophilic Granulomatosis with Z Polyangiitis: Clinical Pathology Conference and Review. J AllergyClin Immunol Pract., 2018; 6(5): 1496\u20131504.","DOI":"10.1016\/j.jaip.2018.07.001"},{"key":"625711r35","doi-asserted-by":"crossref","unstructured":"Pu\u00e9chal X., Pagnoux C., Baron G. et al.: Adding Azathioprine to Remission--Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis(Churg-Strauss), Microscopic polyangiitis, or Polyarteritis Nodosa WithoutPoor Prognosis Factors: A Randomized, Controlled Trial. Arthritis Rheumatol (Hoboken, NJ)., 2017; 69(11): 2175\u20132186.","DOI":"10.1002\/art.40205"},{"key":"625711r36","unstructured":"Terrier B., Pugnet G., de Moreuil C. et al.: Rituximab versus ConventionalTherapeutic Strategy for Remission Induction in Eosinophilic Granulomatosiswith polyangiitis: A Double-blind, Randomized, Controlled Trial [abstract].Arthritis Rheumatol., 2021; 73 (suppl 9). https:\/\/acrabstracts.org\/abstract\/rituximab-versus-conventional-therapeutic-strategy-for-remission-inductionin-eosinophilic-granulomatosis-with-polyangiitis-a-double-blind-randomized--controlled-trial\/ (30.12.2022)."},{"key":"625711r37","doi-asserted-by":"crossref","unstructured":"Wechsler M.E., Akuthota P., Jayne D. et al.: Mepolizumab or Placebo for Eosinophilic Granulomatosis with polyangiitis. N Engl J Med., 2017; 376(20):1921\u20131932.","DOI":"10.1056\/NEJMoa1702079"},{"key":"625711r38","doi-asserted-by":"crossref","unstructured":"Chung S.A., Langford C.A., Maz M. et al.: 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of AntineutrophilCytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken).,2021; 73(8): 1088\u20131105.","DOI":"10.1002\/acr.24634"},{"key":"625711r39","doi-asserted-by":"crossref","unstructured":"Hellmich B., Sanchez-Alamo B., Schirmer J.H. et al.: EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. AnnRheum Dis., 2024; 83(1): 30\u201347.","DOI":"10.1136\/ard-2024-225606"},{"key":"625711r40","doi-asserted-by":"crossref","unstructured":"Guillevin L., Lhote F., Gayraud M. et al.: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore)., 1996; 75(1): 17\u201328.","DOI":"10.1097\/00005792-199601000-00003"},{"key":"625711r41","doi-asserted-by":"crossref","unstructured":"Samson M., Pu\u00e9chal X., Devilliers H. et al.: Long-term outcomes of 118 patientswith eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)enrolled in two prospective trials. J Autoimmun., 2013; 43: 60\u201369.","DOI":"10.1016\/j.jaut.2013.03.003"},{"key":"625711r42","doi-asserted-by":"crossref","unstructured":"Guillevin L., Pagnoux C., Seror R. et al.: The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore)., 2011; 90(1): 19\u201327.","DOI":"10.1097\/MD.0b013e318205a4c6"},{"key":"625711r43","doi-asserted-by":"crossref","unstructured":"Geetha D., Hruskova Z., Segelmark M. et al. Rituximab for treatment of severerenal disease in ANCA associated vasculitis. J Nephrol., 2016; 29(2): 195\u2013201.","DOI":"10.1007\/s40620-015-0208-y"},{"key":"625711r44","doi-asserted-by":"crossref","unstructured":"Pu\u00e9chal X., Pagnoux C., Baron G. et al.: Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.Rheumatology (Oxford)., 2019; 58(12): 2107\u20132116.","DOI":"10.1093\/rheumatology\/kez250"},{"key":"625711r45","doi-asserted-by":"crossref","unstructured":"Bettiol A., Urban M.L., Dagna L. et al.: Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.Arthritis Rheumatol (Hoboken, NJ)., 2022; 74(2): 295\u2013306.","DOI":"10.1002\/art.41943"},{"key":"625711r46","doi-asserted-by":"crossref","unstructured":"Manka L.A., Guntur V.P., Denson J.L. et al.: Efficacy and safety of reslizumabin the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol., 2021; 126(6): 696\u2013701.e1.","DOI":"10.1016\/j.anai.2021.01.035"},{"key":"625711r47","doi-asserted-by":"crossref","unstructured":"Guntur V.P., Manka L.A., Denson J.L. et al.: Benralizumab as a Steroid-SparingTreatment Option in Eosinophilic Granulomatosis with polyangiitis. J AllergyClin Immunol Pract., 2021; 9(3): 1186\u20131193.e1.","DOI":"10.1016\/j.jaip.2020.09.054"},{"key":"625711r48","doi-asserted-by":"crossref","unstructured":"Shomali W., Gotlib J.: World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. AmJ Hematol., 2019; 94(10): 1149\u20131167.","DOI":"10.1002\/ajh.25617"},{"key":"625711r49","doi-asserted-by":"crossref","unstructured":"Ogbogu P.U., Bochner B.S., Butterfield J.H. et al.: Hypereosinophilic syndrome:A multicenter, retrospective analysis of clinical characteristics and response totherapy. J Allergy Clin Immunol., 2009; 124(6): 1319\u20131325.e3.","DOI":"10.1016\/j.jaci.2009.09.022"},{"key":"625711r50","doi-asserted-by":"crossref","unstructured":"Whitehouse M.W.: Anti-inflammatory glucocorticoid drugs: reflections after 60 years. Inflammopharmacology., 2011; 19(1): 1\u201319.","DOI":"10.1007\/s10787-010-0056-2"},{"key":"625711r51","doi-asserted-by":"crossref","unstructured":"Roufosse F., Kahn J.E., Rothenberg M.E. et al.: Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol., 2020; 146(6): 1397\u20131405.","DOI":"10.1016\/j.jaci.2020.08.037"},{"key":"625711r52","doi-asserted-by":"crossref","unstructured":"Chen M.M., Roufosse F., Wang S.A. et al.: An International, Retrospective Studyof Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.J allergy Clin Immunol Pract., 2022; 10(5): 1217\u20131228.e3.","DOI":"10.1016\/j.jaip.2022.02.006"}],"container-title":["Otolaryngologia Polska"],"original-title":[],"link":[{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0054.8684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0054.8684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:11:14Z","timestamp":1759327874000},"score":1,"resource":{"primary":{"URL":"https:\/\/otolaryngologypl.com\/gicid\/01.3001.0054.8684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0054.8684","relation":{},"ISSN":["0030-6657","2300-8423"],"issn-type":[{"value":"0030-6657","type":"print"},{"value":"2300-8423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]}}}